Tenogenic differentiation protocol in xenogenic-free media enhances tendon-related marker expression in ASCs.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
07
2018
accepted:
29
01
2019
entrez:
13
2
2019
pubmed:
13
2
2019
medline:
12
11
2019
Statut:
epublish
Résumé
Adipose-derived stem cells (ASCs) are multipotent and immune-privileged mesenchymal cells, making them ideal candidates for therapeutic purposes to manage tendon disorders. Providing safe and regulated cell therapy products to patients requires adherence to good manufacturing practices. To this aim we investigated the in vitro tenogenic differentiation potential of ASCs using a chemically defined serum-free medium (SF) or a xenogenic-free human pooled platelet lysate medium (hPL) suitable for cell therapy and both supplemented with CTGF, TGFβ-3, BMP-12 and ascorbic acid (AA) soluble factors. Human ASCs were isolated from 4 healthy donors and they were inducted to differentiate until 14 days in both hPL and SF tenogenic media (hPL-TENO and SF-TENO). Cell viability and immunophenotype profile were analysed to evaluate mesenchymal stem cell (MSC) characteristics in both xenogenic-free media. Moreover, the expression of stemness and tendon-related markers upon cell differentiation by RT-PCR, protein staining and cytofluorimetric analysis were also performed. Our results showed the two xenogenic-free media well support cell viability of ASCs and maintain their MSC nature as demonstrated by their typical immunophenototype profile and by the expression of NANOG, OCT4 and Ki67 genes. Moreover, both hPL-TENO and SF-TENO expressed significant high levels of the tendon-related genes SCX, COL1A1, COL3A1, COMP, MMP3 and MMP13 already at early time points in comparison to the respective controls. Significant up-regulations in scleraxis, collagen and tenomodulin proteins were also demonstrated at in both differentiated SF and hPL ASCs. In conclusion, we demonstrated firstly the feasibility of both serum and xenogenic-free media tested to culture ASCs moving forward the GMP-compliant approaches for clinical scale expansion of human MSCs needed for therapeutical application of stem cells. Moreover, a combination of CTGF, BMP-12, TGFβ3 and AA factors strongly and rapidly induce human ASCs to differentiate into tenocyte-like cells.
Identifiants
pubmed: 30753235
doi: 10.1371/journal.pone.0212192
pii: PONE-D-18-18259
pmc: PMC6372228
doi:
Substances chimiques
Antigens, Differentiation
0
Culture Media
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0212192Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Cell Biochem. 2013 May;114(5):1039-49
pubmed: 23129214
Front Physiol. 2016 Aug 19;7:354
pubmed: 27594842
J Clin Invest. 1997 Jul 15;100(2):321-30
pubmed: 9218508
PLoS One. 2013 Oct 14;8(10):e77613
pubmed: 24155967
N Engl J Med. 2006 Oct 19;355(16):1730-5
pubmed: 17050899
Stem Cell Res Ther. 2013 Mar 07;4(2):27
pubmed: 23497764
Development. 2009 Apr;136(8):1351-61
pubmed: 19304887
J Orthop Res. 2001 Nov;19(6):1199-202
pubmed: 11781024
Birth Defects Res C Embryo Today. 2013 Sep;99(3):203-222
pubmed: 24078497
Cell Physiol Biochem. 2015;35(5):1831-45
pubmed: 25833297
Cytotherapy. 2009;11(7):958-72
pubmed: 19903107
J Orthop Res. 2011 Sep;29(9):1351-60
pubmed: 21437969
Cytotherapy. 2013 Jun;15(6):641-8
pubmed: 23570660
Cancer Immunol Immunother. 2000 Jun;49(3):152-6
pubmed: 10881694
Sci Rep. 2017 Aug 29;7(1):9904
pubmed: 28851944
J Biol Chem. 2007 Oct 26;282(43):31166-73
pubmed: 17716974
Int J Periodontics Restorative Dent. 2018 Jan/Feb;38(1):127-135
pubmed: 29240214
Scand J Med Sci Sports. 2000 Dec;10(6):312-20
pubmed: 11085557
Cytotherapy. 2008;10(8):784-95
pubmed: 18951271
Br J Sports Med. 2007 Aug;41(8):e10; discussion e10
pubmed: 17062654
Cytotherapy. 2016 Jan;18(1):99-112
pubmed: 26719200
J Hand Surg Am. 2002 Jul;27(4):615-20
pubmed: 12132085
J Cell Mol Med. 2013 Jan;17(1):168-80
pubmed: 23305553
Regen Med. 2015;10(6):729-43
pubmed: 25565145
Rheumatology (Oxford). 2004 Feb;43(2):131-42
pubmed: 12867575
Cell Transplant. 2015;24(3):509-20
pubmed: 25654771
J Shoulder Elbow Surg. 2012 Feb;21(2):181-90
pubmed: 22244061
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Cell. 1998 Oct 30;95(3):379-91
pubmed: 9814708
J Musculoskelet Neuronal Interact. 2006 Apr-Jun;6(2):181-90
pubmed: 16849830
Development. 2001 Oct;128(19):3855-66
pubmed: 11585810
Tissue Eng Part A. 2016 Mar;22(5-6):513-23
pubmed: 26919401
J Plast Reconstr Aesthet Surg. 2012 Dec;65(12):1712-9
pubmed: 22771087
PLoS One. 2013 Dec 30;8(12):e83734
pubmed: 24386267
J Hand Surg Am. 2008 Dec;33(10):1834-42
pubmed: 19084187
Connect Tissue Res. 2013;54(1):62-9
pubmed: 23020676
Stem Cells. 2009 Sep;27(9):2331-41
pubmed: 19544413
J Orthop Res. 2003 Jul;21(4):617-21
pubmed: 12798060
Nat Med. 2007 Oct;13(10):1219-27
pubmed: 17828274
Cell Death Dis. 2017 Oct 12;8(10):e3116
pubmed: 29022912
J Tissue Eng Regen Med. 2017 Sep;11(9):2525-2536
pubmed: 27098985
J Clin Invest. 2010 Sep;120(9):3340-9
pubmed: 20679726
Biomed Res. 2010 Feb;31(1):27-34
pubmed: 20203417
Arch Pathol. 1964 Jul;78:69-72
pubmed: 14150734
Rev Esp Cir Ortop Traumatol. 2015 Jan-Feb;59(1):3-8
pubmed: 25242729
J Vis Exp. 2009 Oct 30;(32):
pubmed: 19881465
J Exp Orthop. 2018 Sep 24;5(1):38
pubmed: 30251203
J Cell Physiol. 2013 Aug;228(8):1762-73
pubmed: 23359523
Genet Mol Res. 2014 Dec 12;13(4):10434-49
pubmed: 25511027
Dev Biol. 2006 Oct 1;298(1):234-47
pubmed: 16876153
Cell Physiol Biochem. 2017;44(3):1078-1092
pubmed: 29179206
Biomaterials. 2012 Mar;33(7):2137-44
pubmed: 22177622
Injury. 2014 Oct;45 Suppl 4:S22-7
pubmed: 25384471
Cryobiology. 2014 Oct;69(2):211-6
pubmed: 25037024
PLoS One. 2012;7(10):e47559
pubmed: 23133515
Stem Cells Int. 2016;2016:6737345
pubmed: 27057174